Grant ID DP150051
Awarded On November 19, 2014
Title Targeting the DC-HIL Receptor for Anti-Cancer Immunotherapy
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director Kiyoshi Ariizumi
Cancer Sites Bladder, Breast, Cervix Uteri, Colorectal, Kidney and Renal Pelvis, Lung and Bronchus, Melanoma, Pancreas, Prostate, Skin
Contracted Amount $1,163,655
Lay Summary

Despite new advances in cancer treatments, survival of patients with advanced or widespread cancer remains poor because many cancers can weaken the immune system by activating a special type of white blood cells called myeloid-derived suppressor cells (MDSC) that prevents natural killing of cancer cells.

We discovered that mice and patients with melanoma (but not healthy mice or individuals) express a protein (termed DC-HIL) on the surface of MDSC that is responsible for their ability to prevent natural killing of cancer cells. Taking away the DC-HIL gene or blocking its function (through a specific antibody) stops the activation and expansion of MDSC, reactivates the cancer-killing ability...

Read More